Concentration Limits by Market: What to Document Before You Ship

A market-by-market guide to whitening concentration limits by market — peroxide and PAP ceilings, required documentation, and what distributors must collect before shipping.

Whitening Concentration Limits by Market: What to Document Before You Ship

Understanding whitening concentration limits by market is not a compliance formality you hand off after purchase orders are placed. It is a sourcing constraint that determines which formulations you can legally sell in a given territory, what documentation your supplier must produce before the first shipment clears customs, and whether your product enters as a cosmetic or must be registered as a drug or medical device. Getting this wrong at the sourcing stage means reformulation costs, shipment holds, or product recalls — not a compliance footnote.

This guide is structured for distributors, private-label brand owners, and retailers actively sourcing whitening products for specific markets. Each section identifies the regulatory ceiling, the classification logic, and the exact documentation your supplier must produce before you commit to volume.

US Market: FDA Classification Logic and Label Documentation

In the United States, hydrogen peroxide-based whitening products occupy a regulatory grey zone with real commercial consequences. Products marketed with drug claims — framing "whitens teeth" as a therapeutic outcome — may fall under FDA's OTC drug monograph framework. Products positioned purely as cosmetics carry different but equally specific documentation obligations.

For cosmetic-classified whitening products, FDA requires all ingredients to be listed in descending order of predominance. Ingredients present at concentrations of 1% or less may be listed after all higher-concentration ingredients, in any order. Color additives are treated separately and may appear at the end of the ingredient declaration regardless of concentration. These rules, detailed in FDA's Summary of Cosmetics Labeling Requirements, are not optional — non-compliant labeling is a direct basis for regulatory action.

The practical implication for distributors: your supplier must provide a full formulation disclosure confirming the exact concentration of every ingredient, not just the active. That is the only way to verify that your label's ingredient order is accurate and defensible. FDA's Cosmetics Guidance Documents reflect current agency thinking on how concentration-related decisions align with regulatory expectations — reviewing them before finalizing label copy is standard practice for any compliant US launch.

Request a Certificate of Formulation confirming exact percentage by weight (% w/w) for every ingredient.
Verify that your label designer has applied the 1% threshold rule correctly to ingredient ordering.
If your product contains color additives, confirm they are listed separately and are FDA-approved for oral use.

EU and UK: Concentration Ceilings and Safety Dossier Requirements

The EU Cosmetics Regulation (EC) No 1223/2009 sets explicit maximum concentration limits for hydrogen peroxide in tooth whitening products. Formulations containing between 0.1% and 6% hydrogen peroxide are classified as cosmetics — but restricted to professional dental use for the initial application cycle before consumer supply is permitted. Products exceeding 6% hydrogen peroxide cannot legally be sold as cosmetics in the EU. A different regulatory pathway applies entirely.

Every cosmetic placed on the EU market must be supported by a Product Information File (PIF), which includes a Cosmetic Product Safety Report (CPSR) prepared and signed by a qualified safety assessor. The CPSR must address the specific concentration of each ingredient, including any regulated residues or contaminants. EU rules distinguish between formulation ingredients and regulated residues — directly relevant when your supplier sources raw hydrogen peroxide or carbamide peroxide, since maximum residue limits for contaminants are enforced separately from the stated active concentration.

Post-Brexit, Great Britain operates under the GB Cosmetics Regulation, which mirrors EU substance requirements but mandates a separate UK Responsible Person designation and notification via the UK SCPN system. Northern Ireland continues to follow EU rules. Distributors launching in both markets must maintain two parallel documentation sets — there is no shortcut.

EU and UK Documentation Checklist

Product Information File with full formulation and concentration for each ingredient
Cosmetic Product Safety Report signed by a qualified assessor
EU or UK Responsible Person designation and notification filing
Supplier confirmation that hydrogen peroxide concentration does not exceed 6%
Contaminant and heavy metal testing reports aligned with EU residue limits

Canada, Australia, and GCC: Whitening Concentration Limits Distributors Underestimate

These three markets are consistently underestimated in regulatory complexity — particularly by distributors who have navigated US or EU compliance and assume the frameworks transfer.

Canada: Health Canada classifies most hydrogen peroxide whitening products above certain thresholds as natural health products or drugs, triggering pre-market licensing rather than simple cosmetic notification. Canada's Cosmetic Regulations require manufacturers or importers to notify Health Canada within ten days of first sale. Amendments published in the Canada Gazette (SOR/2024-63) expanded the number of standardized concentration ranges from seven to thirteen, giving suppliers more precise disclosure options when reporting ingredient concentrations. Your supplier's formulation documentation must now align with these updated ranges — a detail that directly affects how concentration data is submitted and verified by Health Canada reviewers.

Australia: The Therapeutic Goods Administration (TGA) regulates hydrogen peroxide-containing whitening products at concentrations above 3% as therapeutic goods, requiring inclusion in the Australian Register of Therapeutic Goods (ARTG) before sale. Products at or below 3% may be regulated as cosmetics under the Industrial Chemicals Act, but the classification boundary is strictly enforced. Confirm your product's concentration against this threshold before committing to a formulation — not after.

GCC: Member states including Saudi Arabia and the UAE follow GCC Standardization Organization (GSO) technical regulations for cosmetics, which reference EU concentration limits as a baseline but apply additional national requirements for registration, Arabic labeling, and halal certification in specific markets. EU compliance documentation does not transfer directly. Local registration with the relevant national authority is required.

PAP Formulations: Regulatory Classification Across Markets

Phthalimidoperoxycaproic acid (PAP) is the active ingredient in peroxide-free whitening formulations that have gained significant traction in premium retail and professional channels. Its regulatory status differs from hydrogen peroxide in ways that directly shape market access strategy.

In the EU, PAP is not listed in Annex II (prohibited substances) or Annex III (restricted substances) of the Cosmetics Regulation, which means it can be used in cosmetic formulations subject to safety assessment. The absence of a harmonized maximum concentration, however, places greater responsibility on the safety assessor to justify the concentration used. This raises the burden on the CPSR, not lowers it.

In the US, PAP-based products positioned as cosmetics avoid the OTC drug monograph framework that applies to peroxide-based whitening claims. The same FDA labeling rules still apply: full ingredient disclosure, correct concentration-based ordering, and accurate label claims.

In Canada, PAP formulations may avoid the drug classification threshold that peroxide products trigger, potentially enabling cosmetic notification rather than pre-market licensing — but this depends on the specific claims made on the label. In Australia, PAP does not fall under TGA's therapeutic goods threshold in the way peroxide does, which makes it a strategically useful formulation for distributors seeking to avoid ARTG registration requirements.

When co-developing a PAP-based product for multiple markets, full concentration disclosure, safety data, and stability testing remain mandatory. The regulatory classification may be simpler; the supplier documentation stack is not.

The Documentation Stack: What to Collect Before Your First Shipment

Regardless of market, a compliant launch requires a defined set of supplier documents. Collecting these before placing volume orders — not after — is the operational discipline that separates distributors who scale cleanly from those facing holds and reformulations mid-launch.

Document	Purpose	Markets Where Required
Certificate of Formulation	Confirms exact concentration (% w/w) of every ingredient, including actives and excipients	All markets
Certificate of Analysis (CoA)	Batch-level testing confirming active concentration and absence of prohibited contaminants	All markets
Heavy Metal and Contaminant Testing Report	Confirms compliance with jurisdiction-specific residue limits for arsenic, lead, mercury, and chromium	US, EU, UK, Canada, Australia
Cosmetic Product Safety Report (CPSR)	Qualified assessor sign-off on formulation safety at stated concentrations	EU, UK
Stability and Compatibility Testing	Confirms active concentration remains within stated range over shelf life	All markets; mandatory for EU CPSR
Regulatory Classification Letter	Supplier's written confirmation of how the product is classified in each target market	Canada, Australia, GCC
ISO / GMP Certification	Confirms manufacturing facility meets quality standards required by import authorities	EU, UK, GCC, Australia

FDA's cosmetics hub and guidance documents are a practical starting point for verifying which documents align with current US agency expectations. For EU and UK, the PIF and CPSR are non-negotiable — no Responsible Person will accept a product without them in place before notification.

When Concentration Limits Force Reformulation

The most common trigger for reformulation is a concentration ceiling mismatch. A product formulated at 10% hydrogen peroxide for a US professional channel cannot be sold as a cosmetic in the EU, where the ceiling is 6%. That is not a labeling fix — it requires a new formulation, new stability data, and a new safety assessment. Budget and timeline implications are significant.

A second common scenario: a product clears US cosmetic notification but is flagged by the TGA in Australia because concentration exceeds the 3% threshold. Distributors who did not confirm the Australia-specific ceiling before finalizing the formulation face either ARTG registration — a materially longer and more expensive pathway — or a full reformulation cycle.

The corrective is straightforward: map your target markets and their concentration ceilings before selecting a formulation, not after. Private-label ready formulations co-developed with market-specific ceilings in mind will clear documentation review faster, carry lower reformulation risk, and give your Responsible Person or regulatory consultant a cleaner file to work with from day one.

For distributors building multi-market whitening lines, reviewing formulation options against each jurisdiction's whitening concentration limits by market at the briefing stage — before a single gram is manufactured — is the single highest-leverage compliance decision in the sourcing process.

References

Disclaimer

This article is for general informational purposes only and does not constitute sourcing, legal, or regulatory advice. Always conduct your own due diligence and consult qualified legal or compliance professionals before making purchasing or compliance decisions. WhiteningBright makes no warranties as to the completeness or accuracy of the information, and any reliance is at your own risk.